Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health
STONY BROOK, NY / ACCESSWIRE / June 13, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced that the New York State Department of Health ("NYSDOH") approved the Company's TR8™ PGx ("TR8") pharmacogenomic (PGx) testing service. The Company is currently in discussions to provide large-scale testing to enterprise customers, healthcare networks, and concierge physicians seeking to add PGx testing to their test menu.
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
The S&P 500 has hit more than one record high this year, and technology stocks have led the gains. It's a great idea to get in on stocks that have remained in the doldrums but could have a bright future.
After Plunging -40.22% in 4 Weeks, Here's Why the Trend Might Reverse for Ginkgo Bioworks (DNA)
Ginkgo Bioworks (DNA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea(TM) IVT Platform
Patent covers the Composition of the Company's Proprietary Linea™ RNAP, a Core Technology Empowering the Linea™ IVT Platform Patent Application Also Currently Pending in Key International Markets STONY BROOK, NY / ACCESSWIRE / June 5, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent application 18/302,247, entitled "Compositions and Methods for RNA Synthesis." The resulting patent will cover the composition of the Company's chemically modified RNA polymerase enzyme branded Linea™ RNAP, with expected patent protection into 2041.
3 Sorry Biotech Stocks to Sell in May While You Still Can
Morgan Stanley recently released its bullish take on the biotech space, driven by anticipated interest rate cuts and a surge in mergers and acquisitions (M&A) activity. The analyst firm states biotech stocks typically outshine the market just before a rate cut.
Ginkgo Bioworks Stock: Bull vs. Bear
Ginkgo is embarking on a cost-cutting plan that could pave the path to profitability and share performance. The main bear case against Ginkgo is there's no compelling reason to buy the stock right now.
Should You Buy the Dip on Ginkgo Bioworks Stock?
Ginkgo Bioworks is still struggling with operating efficiency. Management is signaling that its processes may be streamlined.
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
Cathie Wood likes to invest in risky biotech stocks. Ginkgo Bioworks has ambitions to disrupt biopharma manufacturing.
3 Things You Need to Know if You Buy Ginkgo Bioworks Today
Ginkgo Bioworks is using a unique approach to laboratory automation. It's also spending a lot of its finite supply of money on this endeavor.
Down 72%. Is Ginkgo Bioworks a Buy on the Dip?
Shares of Ginkgo Bioworks have been beaten severely in response to heavy financial losses. The company's cell foundry could disrupt the biopharmaceutical manufacturing industry.
Ginkgo Bioworks Stock Has 37.5% Downside, According to 1 Wall Street Analyst
Ginkgo Bioworks (NYSE: DNA) stock has dropped more than 10% since its latest quarterly report showing a more than 53% decline in Q1 revenue and continued net losses from its business. BTIG analyst Mark Massaro downgraded Ginkgo stock to sell, and lowered his price on this biotech penny stock to just $0.50. It closed Friday at $0.80, so that would be a 37.5% drop. Why rate Ginkgo stock a sell? Where shall I begin? Massaro is most concerned with management commentary that new "cell programs" -- of which the company expects to add 100 this year -- are no longer a great forecaster of revenue growth, and may give investors a false impression of the company's revenue growth rate. The analyst wrote that it will be "difficult to model how new cell program adds will flow into revenue growth in 2024, 2025, and beyond." For that reason, as well as a change in business plan to offering "lab data as a service," Massaro feels it's safest to avoid the stock for now. I agree. Ginkgo cut costs significantly in the quarter, but largely through cuts in head count and research and development -- troubling moves in a supposed growth stock. Adding to its troubles, the company received a warning from the NYSE that it's at risk of being delisting if the stock price does not rise soon. That's often a precursor to a company announcing a reverse stock split -- yet another no-no for growth stocks. Although possessing enough cash to keep it going for about two years at its current burn rate, I'm just not sure this company is going anywhere fast. To me, that makes Ginkgo stock a sell. Before you buy stock in Ginkgo Bioworks, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ginkgo Bioworks wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $566,624!* Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*. See the 10 stocks » *Stock Advisor returns as of May 13, 2024 Rich Smith has no position in any of the stocks mentioned. The Motley Fool recommends Roche Ag. The Motley Fool has a disclosure policy. Ginkgo Bioworks Stock Has 37.5% Downside, According to 1 Wall Street Analyst was originally published by The Motley Fool
Ginkgo Bioworks Stock Has 37.5% Downside, According to 1 Wall Street Analyst
Ginkgo Bioworks reported a steep fall in revenue but lower losses earlier this month. Losses mainly shrank due to cuts in workforce and research and development; not good signs for a growth stock.
